ProMetic Life Sciences Inc. (PLI) 2010年年度报告「TSX」.pdf

1、 Life Sciences Inc.2010 Annual ReportWho We areour name defines who we are:ProMetic is derived from the words Protein and Mimetic.at ProMetic we design small chemical molecules that mimic unique and specific interactions between proteins.These proprietary chemical structures can be used in a myriad

2、of commercial applications when incorporated into filters.ProMetic creates affinity filters that bind and recover high levels of the valuable therapeutic proteins.These same technologies allow us to create filters that bind and remove high concentrations of pathogens.These proprietary chemical struc

3、tures also form the basis for our drug discovery platform.WhaT We doProMetics technologies are used to remove pathogens from blood,and extract and recover valuable proteins from plasma,as well as providing purification technologies to the biopharmaceutical industry.ProMetic also develops novel,orall

4、y active,first-in-class therapeutics for unmet medical needs in the fields of hematology,oncology,nephrology,fibrosis and autoimmune diseases.Overview Significant events .1Value drivers.4Message to Shareholders .8Selected Financial Information .10Management Team .11Md&a.13Financial StatementsConsoli

5、dated Financial Statements.39Consolidated Balance Sheets.41Consolidated Statement of operations and Comprehensive Loss .42Consolidated Statements of Contributed Surplus .43Consolidated Statement of accumulated other Comprehensive Loss.43Consolidates Statements of Cash Flows.44Notes to Financial Stat

6、ements .45Board of directors.77Corporate Information .78ProMetic entered into a collaboration agreement with Abraxis BioScience,Inc.(“Abraxis”)to develop and commercialize various applications deriving from ProMetics prion capture technology platform.ProMetic finalized an equity investment of$3 Mill